Welcome to
Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. This independent business unit within Pfizer Inc. was established to enhance innovation while still drawing on the expertise and resources of the world's largest research-based pharmaceutical company.

Advancing science

As science in oncology continues to evolve, Pfizer is pursuing research centred around a personalised approach to cancer treatment and tailoring therapy based on the molecular and/or biologic make-up of the disease, to develop compounds that will extend lives for patients.

Developing breakthrough medicines

Pfizer Oncology has a robust pipeline consisting of over 20 biologics and small molecules in development, including several first-in-class compounds. We are currently running over 200 clinical trials, in some of the most prevalent and difficult-to-treat cancers, such as lung, prostate, colorectal, breast, liver and kidney cancer. Our goal is to provide patients with better, more customised treatment options with longer survival rates in various tumour types.

Working together

Pfizer Oncology is committed to partnerships with professional and patient organisations that deliver benefits to patients including disease management tools, awareness of clinical trial options and access to new medicines.

Working together, we strive to transform treatment by
targeting the right drug for the right patient at the right time.